NR3C2 and Gynecomastia: The first MR blocker identified was spironolactone, a nonselective agent that also had affinity for progesterone and androgen receptors; this lack of selectivity and non-MR blocking activity contributed to the occurrence of problematic adverse events, including menstrual abnormalities in women and sexual dysfunction with painful gynecomastia in men [11–13].